Sharma, P., López-Tarruella, S., García-Saenz, J.A., et al. (2017) Efficacy of Neoadjuvant Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 23, 649-657.
https://doi.org/10.1158/1078-0432.CCR-16-0162

has been cited by the following article:

• TITLE: A Single Centre Experience with Phenotype Dependent Perioperative Chemotherapy for Primary Breast Cancer

  AUTHORS: Tamás Kullmann, Kofi Agyemang-Prempeh, Adél Ambrus, Gabriella Herodek, Balázs Hillier, Károly Kocsis, Ilona Laszip, Mária Mák, Tamás Pintér, István Sipőcz

  KEYWORDS: Breast Cancer, Carboplatin, Trastuzumab, Adjuvant, Neoadjuvant

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.1, January 4, 2019

  ABSTRACT: Background: Standard adjuvant or neo-adjuvant chemotherapy of primary breast cancers consists of docetaxel and the combination of anthracyclin-cyclophosphamide in two steps. According to international literature, the neo-adjuvant treatment of triple negative tumours by the combination of docetaxel-carboplatin allows a high rate of pathological complete remission and the adjuvant treatment of small, node negative HER2+ tumours by the combination of paclitaxel-trastuzumab allows a negligible recurrence rate together with a very good tolerance. Methods: Our aim was the retrospective analysis of the alternative chemotherapy regimens in our patient population. Results: The neo-adjuvant docetaxel-carboplatin allowed a 55% pathological complete remission rate among 20 patients. With the adjuvant paclitaxel-trastuzumab, we did not notice any recurrence among 5 patients at a median follow-up of 18 months. Conclusion: Our results correspond to the literature data. The spread of the protocols in the clinical practice is proposed.